Follow-up analysis of sex hormone levels and prognosis in women after hematopoietic stem cell transplantation
10.3760/cma.j.cn112138-20230526-00272
- VernacularTitle:造血干细胞移植后女性性激素水平与预后随访分析
- Author:
Qianwen XU
1
;
Yuanyuan DU
;
Kangkang LYU
;
Mimi XU
;
Chengyuan GU
;
Huizhu KANG
;
Shanglong FENG
;
Yuejun LIU
;
Depei WU
;
Yue HAN
Author Information
1. 苏州大学附属第一医院血液科 江苏省血液研究所 国家血液系统疾病临床医学研究中心 苏州大学造血干细胞移植研究所血液学协同创新中心，苏州 215006
- Keywords:
Hematopoietic stem cell transplantation;
Follicle stimulating hormone;
Premature ovarian failure;
Hormone replacement therapy
- From:
Chinese Journal of Internal Medicine
2023;62(11):1303-1310
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the levels of sex hormone and fertility in female patients after hematopoietic stem cell transplantation (HSCT), as well as their correlation with conditioning regimens, and analyse the effect of hormone replacement therapy (HRT) in young women after HSCT.Methods:Retrospective case series study. The clinical data of 147 women who underwent HSCT in the First Affiliated Hospital of Soochow University from January 2010 to January 2021 were retrospectively analyzed. The sex hormone levels were measured and followed-up, and the survival, menstrual fertility and the use of HRT of the patients were also followed-up. The sex hormone levels were measured after transplantation, and the ovarian function was evaluated. Independent sample t test and χ2 test were used for comparison between the two groups. Results:The median age of the 147 patients was 26 (range, 10-45) years. Of them, 135 patients received allogeneic HSCT and 12 patients received autologous HSCT. Furthermore, 129 patients received myeloablative conditioning, and 18 patients received reduced conditioning dose. The median follow-up time was 50 months (range, 18-134 months). Five patients died of disease recurrence during follow-up. Of the 54 patients with subcutaneous injection of zoladex, three recovered menstruation spontaneously after transplantation, and all of them were myeloablative conditioning patients, one patient gave birth to twins through assisted reproductive technology. Ninety-three patients did not use zoladex before conditioning, two patients with aplastic anemia with non-myeloablative transplantation resumed menstruation spontaneously, and conceived naturally. The level of follicle stimulating hormone after transplantation in patients receiving myeloablative conditioning regimen was significantly higher than that in patients receiving reduced-dose conditioning regimen [(95.28±3.94) U/L vs. (71.85±10.72) U/L, P=0.039]. Among 147 patients, 122 patients developed premature ovarian failure, 83 patients received sex hormone replacement therapy after transplantation, and 76 patients recovered menstruation and improved endocrine function. Conclusions:The incidence of premature ovarian failure is high in female patients after HSCT, and patients have a chance at natural conception. Reducing the dose of conditioning regimen and the application of zoladex before transplantation can reduce ovarian of conditioning drugs. HRT after transplantation can partially improve the endocrine function of patients.
